{"product_id":"carotid-ultrasound-why-measuring-plaque-not-just-artery-wall-thickness-matters-for-your-heart-and-brain-health","title":"Carotid Ultrasound: Why Measuring Plaque, Not Just Artery Wall Thickness, Matters for Your Heart and Brain Health","description":"\u003cp\u003eWhen it comes to preventing heart attacks and strokes, doctors have long used ultrasound to look at the carotid arteries — the main blood vessels in your neck that supply your brain. But a major new analysis of nearly 10,000 Brazilian adults, highlighted in this expert editorial, reveals a crucial point: the different things ultrasound measures in your arteries are \u003cem\u003ebiologically distinct\u003c\/em\u003e. The thickness of the artery wall (called intima-media thickness, or IMT), the amount of plaque buildup, and the degree of narrowing (stenosis) each respond to different risk factors, are influenced by different genes, and respond differently to medication. Most importantly, decades of research show that measuring \u003cstrong\u003eplaque burden\u003c\/strong\u003e — the total amount of plaque — predicts heart attacks and strokes far better than measuring wall thickness alone. This article breaks down what these distinct \"ultrasound phenotypes\" mean for you and your care.\u003c\/p\u003e\n\n\u003ch1\u003eCarotid Ultrasound: Why Measuring Plaque, Not Just Artery Wall Thickness, Matters for Your Heart and Brain Health\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#phenotypes\"\u003eTwo Measurements, Two Different Meanings\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: What Large Studies Show\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#elsabrasil\"\u003eThe ELSA-Brasil Study: A Closer Look\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#genetics\"\u003eGenetics, Plaque, and New Therapies\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#therapy\"\u003eMeasuring Treatment Response\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Editorial Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations: What Patients Should Know\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eCarotid ultrasound measuring plaque burden, not just IMT, predicts heart attack and stroke risk far better.\u003c\/li\u003e\n\u003cli\u003eIMT is biologically distinct from plaque: it mostly reflects aging and demographics, while plaque reflects treatable risk factors.\u003c\/li\u003e\n\u003cli\u003ePlaque area or volume changes are larger and respond faster to treatment than IMT, making them better for monitoring.\u003c\/li\u003e\n\u003cli\u003eStatin therapy typically requires about 2 years of aggressive lipid lowering before plaque regression is seen.\u003c\/li\u003e\n\u003cli\u003eLifestyle changes like weight loss and blood pressure reduction can measurably reduce artery vessel wall volume in 2 years.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\u003cp\u003eYour carotid arteries are like highways carrying oxygen-rich blood to your brain. When cholesterol and other substances build up inside them, they form \u003cstrong\u003eplaque\u003c\/strong\u003e — a waxy deposit that can grow, rupture, and cause a heart attack or stroke. For years, doctors have used ultrasound to check these arteries, but there's been an important debate: \u003cem\u003ewhich measurement actually predicts danger best?\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eSome doctors measure the thickness of the artery wall's inner two layers (the intima and media), a value called \u003cstrong\u003eintima-media thickness (IMT)\u003c\/strong\u003e. Others measure the actual plaque itself — either its area or volume. Still others measure \u003cstrong\u003estenosis\u003c\/strong\u003e, which is the percentage of narrowing of the artery opening.\u003c\/p\u003e\n\u003cp\u003eThis editorial, written by Dr. J. David Spence of Western University in London, Canada, was published in the journal \u003cem\u003eArteriosclerosis, Thrombosis, and Vascular Biology\u003c\/em\u003e in 2015. It accompanies a large new study from Brazil (the ELSA-Brasil cohort, which included 9,792 participants) that found traditional heart risk factors explain surprisingly little of what IMT actually measures. The editorial pulls together evidence from multiple major studies to argue a critical point: these ultrasound measurements are not interchangeable — they capture \u003cstrong\u003ebiologically distinct\u003c\/strong\u003e processes in your body.\u003c\/p\u003e\n\n\u003ch2 id=\"phenotypes\"\u003eTwo Measurements, Two Different Meanings\u003c\/h2\u003e\n\u003cp\u003eTo understand the debate, you first need to know there are actually \u003cem\u003etwo different kinds\u003c\/em\u003e of IMT measurements used in research — and they are not the same thing. As pointed out by Inaba and colleagues, it is crucial to distinguish between:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMannheim consensus IMT\u003c\/strong\u003e: Measured in the far wall of the distal common carotid artery, where there is no plaque. This measurement reflects thickening of the artery wall itself, not the buildup of plaque.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eARIC-protocol IMT\u003c\/strong\u003e (used in the Atherosclerosis Risk in Communities study and related protocols): This method includes plaque thickness in the measurement at multiple locations, including the carotid bulb (the widened area where the artery branches).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis distinction matters enormously. IMT measured according to the Mannheim consensus does \u003cstrong\u003enot\u003c\/strong\u003e represent atherosclerosis (the disease of plaque buildup). It is another phenotype entirely — a different biological trait.\u003c\/p\u003e\n\u003cp\u003eThere's also a key anatomical principle at work called \u003cstrong\u003ecompensatory enlargement (positive remodeling)\u003c\/strong\u003e, first described by Glagov in 1987. As plaque builds up, the artery actually \u003cem\u003eenlarges\u003c\/em\u003e to accommodate it, so the opening (lumen) doesn't narrow — at least not at first. This means:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque burden\u003c\/strong\u003e reflects the effects of oxidative stress and \u003cem\u003ea lifetime's exposure\u003c\/em\u003e to heart risk factors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStenosis\u003c\/strong\u003e (narrowing) reflects factors that cause plaque \u003cem\u003erupture\u003c\/em\u003e and blood clotting (thrombosis).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAn illustration of this principle: \u003cstrong\u003elipoprotein(a)\u003c\/strong\u003e, or Lp(a) — a clotting factor — is associated with carotid stenosis and occlusion, but not with plaque burden. Different biological pathways, different measurements.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Research Was Conducted\u003c\/h2\u003e\n\u003cp\u003eThis article is an \u003cstrong\u003eeditorial\u003c\/strong\u003e — a type of expert perspective article written by a leading researcher to comment on a new study and place it in the context of existing evidence. It is not a single clinical trial with patients. Instead, it reviews and synthesizes the findings of many large studies, meta-analyses, and clinical trials that together span decades of research.\u003c\/p\u003e\n\u003cp\u003eThe centerpiece is the \u003cstrong\u003eELSA-Brasil study\u003c\/strong\u003e by Santos and colleagues, a large Brazilian cohort study of 9,792 participants that used multiple regression analysis (a statistical method for determining how much of a measured value can be explained by various factors) to determine what predicts IMT. But the editorial also draws on evidence from:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe \u003cstrong\u003eMulti-Ethnic Study of Atherosclerosis (MESA)\u003c\/strong\u003e in the U.S.\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003eTromsø study\u003c\/strong\u003e in Norway (more than 6,000 participants)\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003eAtherosclerosis Risk in Communities (ARIC)\u003c\/strong\u003e study\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003eNorthern Manhattan Study (NOMAS)\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003eCardiovascular Health Study\u003c\/strong\u003e (O'Leary et al.)\u003c\/li\u003e\n  \u003cli\u003eMultiple meta-analyses combining data from thousands of patients worldwide\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: What Large Studies Show\u003c\/h2\u003e\n\u003cp\u003eThe evidence is consistent and powerful: \u003cstrong\u003eplaque measurement beats IMT measurement for predicting risk.\u003c\/strong\u003e Here are the specific findings from major studies.\u003c\/p\u003e\n\n\u003ch3\u003ePlaque Thickness Predicts Cardiovascular Risk\u003c\/h3\u003e\n\u003cp\u003eThe Northern Manhattan Study, led by Rundek and colleagues, found that \u003cstrong\u003eplaque thickness predicts cardiovascular risk\u003c\/strong\u003e. This may be why studies that include plaque thickness in their IMT measurement (like the ARIC protocol) tend to predict risk better — particularly in the elderly.\u003c\/p\u003e\n\n\u003ch3\u003eThe ARIC Study: Added Value of Plaque\u003c\/h3\u003e\n\u003cp\u003eIn the ARIC study, measuring IMT added only 0.08 to the \"area under the curve\" (a statistical measure of predictive accuracy, where 1.0 is perfect prediction and 0.5 is no better than chance) \u003cem\u003ebeyond\u003c\/em\u003e traditional coronary risk factors. But when the \u003cem\u003epresence of plaque\u003c\/em\u003e was added, the improvement jumped to \u003cstrong\u003e0.17\u003c\/strong\u003e — more than double. In plain terms, knowing whether plaque is present greatly improves risk prediction, while knowing the IMT adds relatively little.\u003c\/p\u003e\n\n\u003ch3\u003eMeta-Analyses: IMT Is a Weak Predictor\u003c\/h3\u003e\n\u003cp\u003eA systematic review and meta-analysis by Lorenz and colleagues (2007, published in \u003cem\u003eCirculation\u003c\/em\u003e) found that IMT measured \u003cem\u003ewithout\u003c\/em\u003e plaque is a weak predictor of cardiovascular risk. The PROG-IMT collaborative project (Lorenz, 2012, in \u003cem\u003eThe Lancet\u003c\/em\u003e) went further: \u003cstrong\u003eprogression of IMT over time did not predict cardiovascular events\u003c\/strong\u003e. And a meta-analysis of 41 randomized trials by Costanzo and colleagues (2010, in the \u003cem\u003eJournal of the American College of Cardiology\u003c\/em\u003e) found \u003cstrong\u003eregression of IMT did not predict reduction of cardiovascular events\u003c\/strong\u003e either. In other words, watching IMT go up or down tells you very little about whether you'll actually have a heart attack or stroke.\u003c\/p\u003e\n\n\u003ch3\u003ePlaque Area Is Stronger Than IMT\u003c\/h3\u003e\n\u003cp\u003eA meta-analysis by Inaba and colleagues (2012) concluded that \u003cstrong\u003eplaque area was a stronger predictor of risk than IMT\u003c\/strong\u003e. Adams and Bojara, in a workplace health program study of more than 4,000 participants, found that plaque area and plaque type — but \u003cem\u003enot\u003c\/em\u003e IMT — predicted coronary stenosis and cardiovascular risk.\u003c\/p\u003e\n\n\u003ch3\u003eCoronary Calcium vs. IMT (MESA)\u003c\/h3\u003e\n\u003cp\u003eThe Multi-Ethnic Study of Atherosclerosis (MESA) found that \u003cstrong\u003ecoronary calcium\u003c\/strong\u003e (a measure of calcified plaque in the heart's arteries) predicted cardiovascular risk in the overall population, but \u003cstrong\u003eIMT did not\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003ePlaque Area for Excluding Heart Disease\u003c\/h3\u003e\n\u003cp\u003eBrook and colleagues (2006) reported that \u003cstrong\u003ecarotid total plaque area was more specific for excluding coronary artery stenosis\u003c\/strong\u003e (i.e., a negative test more reliably rules out significant heart artery narrowing) than either IMT or coronary calcium score.\u003c\/p\u003e\n\n\u003ch3\u003eA Study in Coronary Artery Disease Patients\u003c\/h3\u003e\n\u003cp\u003eChan and colleagues (2003) found that among patients with known coronary artery disease, both total plaque area and impaired flow-mediated vasodilation (a measure of blood vessel health) predicted risk. In that study, \u003cstrong\u003eIMT without plaque did not correlate with either measure and did not predict risk\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003ePlaque Echolucency, Not IMT, Predicts Residual Risk\u003c\/h3\u003e\n\u003cp\u003eA study by Uematsu and colleagues (2014) examined patients who had achieved their LDL (\"bad\") cholesterol goals on statin therapy but still had residual risk. The key predictor was \u003cstrong\u003ecarotid plaque echolucency\u003c\/strong\u003e (how dark the plaque appears on ultrasound, indicating softer, more dangerous plaque) — \u003cstrong\u003enot IMT\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eThe Tromsø Study: A Landmark Comparison\u003c\/h3\u003e\n\u003cp\u003eThe largest population-based study measuring both IMT and plaque burden side by side is the \u003cstrong\u003eTromsø study\u003c\/strong\u003e in Norway, with more than 6,000 participants. The results were striking:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eIn the \u003cstrong\u003e7-year follow-up\u003c\/strong\u003e (6,226 persons), IMT in the common carotid did \u003cem\u003enot\u003c\/em\u003e predict coronary risk. IMT in the carotid bulb (which included plaque thickness) was a \u003cem\u003eweak\u003c\/em\u003e predictor. But \u003cstrong\u003etotal plaque area was a strong predictor\u003c\/strong\u003e of coronary risk.\u003c\/li\u003e\n  \u003cli\u003eIn the \u003cstrong\u003e10-year follow-up\u003c\/strong\u003e (6,584 men and women), \u003cstrong\u003eIMT did not predict stroke\u003c\/strong\u003e, whereas \u003cstrong\u003etotal plaque area was a strong predictor of stroke\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eA \u003cstrong\u003e13-year follow-up\u003c\/strong\u003e (Herder and colleagues, 2012) found that total cholesterol, systolic blood pressure, and smoking were stronger predictors of progression of total plaque area than of IMT. By contrast, \u003cstrong\u003esex and age were stronger predictors of IMT\u003c\/strong\u003e — suggesting IMT mostly reflects aging and demographics, not treatable risk factors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eHow Much Do Risk Factors Explain?\u003c\/h3\u003e\n\u003cp\u003ePrevious studies reported that traditional coronary risk factors explained \u003cstrong\u003e52% to 57% of total plaque area\u003c\/strong\u003e, but only \u003cstrong\u003e13% of carotid stenosis\u003c\/strong\u003e. O'Leary and colleagues (Cardiovascular Health Study, using methods that included plaque thickness) found that coronary risk factors explained just \u003cstrong\u003e17% of IMT in the common carotid\u003c\/strong\u003e and \u003cstrong\u003e18% of IMT in the carotid bulb\u003c\/strong\u003e. The Northern Manhattan Study found only \u003cstrong\u003e11% of IMT was explained by traditional risk factors\u003c\/strong\u003e, with age and male sex accounting for most of the explained variance. Glucose and smoking (pack-years) also contributed, and LDL cholesterol was only marginally significant. Even an extended model — adding inflammatory biomarkers, adiponectin, homocysteine, and kidney function — explained only \u003cstrong\u003e16% of the variance\u003c\/strong\u003e, with adiponectin as the only additional significant contributor.\u003c\/p\u003e\n\n\u003ch2 id=\"elsabrasil\"\u003eThe ELSA-Brasil Study: A Closer Look\u003c\/h2\u003e\n\u003cp\u003eInto this landscape comes the ELSA-Brasil study (Santos et al., 2015), which the editorial accompanies. In this large Brazilian cohort of \u003cstrong\u003e9,792 participants\u003c\/strong\u003e, the researchers analyzed how much of IMT could be explained by various factors. Their findings added important nuance.\u003c\/p\u003e\n\u003cp\u003eSantos and colleagues found that their comprehensive set of factors explained a \u003cem\u003ehigher proportion\u003c\/em\u003e of IMT (a higher R² — the statistical \"explained variance\") than previous studies had reported. But the key insight was \u003cem\u003ewhich\u003c\/em\u003e factors did the explaining. Factors such as:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eRace\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePulse pressure\u003c\/strong\u003e (the difference between systolic and diastolic blood pressure)\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eNeck circumference\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e...made a \u003cstrong\u003egreater contribution\u003c\/strong\u003e to predicting IMT (i.e., had higher beta values in the statistical models) than the traditional coronary risk factors like cholesterol, smoking, and blood pressure. Perhaps most tellingly, IMT was predicted \u003cem\u003eless strongly\u003c\/em\u003e among participants with a predicted coronary risk greater than 10% — the very people who most need accurate risk assessment.\u003c\/p\u003e\n\u003cp\u003eEven with all these additional predictors, the total explained variance (the R²) rose to only \u003cstrong\u003e0.3\u003c\/strong\u003e — meaning \u003cstrong\u003e70% of what IMT measures remains unexplained\u003c\/strong\u003e by known risk factors. This powerfully illustrates that IMT is a different biological phenomenon from plaque burden, which is far better explained (52-57%) by traditional risk factors.\u003c\/p\u003e\n\n\u003ch2 id=\"genetics\"\u003eGenetics, Plaque, and New Therapies\u003c\/h2\u003e\n\u003cp\u003eThe biological distinctness of these ultrasound phenotypes is also visible in genetics. Dr. Spence notes that, as would be expected, \u003cstrong\u003egenetic factors for IMT are different from those for plaque burden\u003c\/strong\u003e. Similarly, genetic factors affecting stenosis would be expected to differ, as they would preferentially affect plaque rupture and thrombosis. And genetic factors affecting coronary calcium scores would preferentially affect calcification. This means a person could inherit genes that thicken their artery walls without inheriting genes that cause dangerous plaque — and vice versa.\u003c\/p\u003e\n\u003cp\u003eThese distinctions have practical consequences for clinical trials. The recommended sample size for a study testing whether a therapy changes IMT is approximately \u003cstrong\u003e300 participants per group, followed for 2 years\u003c\/strong\u003e. Why so large and so long? Because the average progression of IMT is tiny — about \u003cstrong\u003e0.15 mm per year\u003c\/strong\u003e — while the spatial resolution (the smallest detail the ultrasound can reliably detect) of carotid ultrasound is about \u003cstrong\u003e0.3 mm\u003c\/strong\u003e. You're trying to measure a change that's half the size of your measuring tool's precision.\u003c\/p\u003e\n\u003cp\u003eBy contrast, two-dimensional (2D) and three-dimensional (3D) measurements of plaque burden change by much larger amounts:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTotal plaque area changes by about \u003cstrong\u003e10 mm² per year\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e3D total plaque volume changes by about \u003cstrong\u003e50 to 100 mm³ per year\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese larger changes are much easier to measure reliably, making plaque measurements far more sensitive for detecting whether a treatment is working.\u003c\/p\u003e\n\n\u003ch2 id=\"therapy\"\u003eMeasuring Treatment Response: Proof That Plaque Responds Faster\u003c\/h2\u003e\n\u003cp\u003eThe editorial highlights several studies showing that plaque measurement can detect treatment effects quickly and with far fewer patients:\u003c\/p\u003e\n\n\u003ch3\u003eStatin Treatment: Rapid Plaque Regression\u003c\/h3\u003e\n\u003cp\u003eIt was possible to show a significant change in carotid plaque volume with \u003cstrong\u003eatorvastatin\u003c\/strong\u003e (a common statin medication) in just \u003cstrong\u003e3 months\u003c\/strong\u003e, using only about \u003cstrong\u003e20 patients per group\u003c\/strong\u003e — a dramatic contrast to the 300 patients and 2 years needed for IMT studies. In this randomized trial:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePatients on \u003cstrong\u003eplacebo\u003c\/strong\u003e: total plaque volume \u003cem\u003eincreased\u003c\/em\u003e by \u003cstrong\u003e16.81 ± 74.10 mm³\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003ePatients on \u003cstrong\u003eatorvastatin\u003c\/strong\u003e: total plaque volume \u003cem\u003eregressed\u003c\/em\u003e by \u003cstrong\u003e−90.25 ± 85.12 mm³\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eThe difference was statistically highly significant (\u003cstrong\u003eP\u0026lt;0.001\u003c\/strong\u003e), meaning there's less than a 0.1% chance this result was due to random chance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFurthermore, a study by Wannarong and colleagues (2013) found that \u003cstrong\u003eprogression of total plaque volume predicted cardiovascular events\u003c\/strong\u003e among patients attending vascular prevention clinics — but progression of IMT or plaque area did not.\u003c\/p\u003e\n\n\u003ch3\u003eVessel Wall Volume: For Patients Without Plaque\u003c\/h3\u003e\n\u003cp\u003eFor patients or study participants who don't yet have plaque, it's still possible to measure something called \u003cstrong\u003evessel wall volume (VWV)\u003c\/strong\u003e — the total volume of the artery wall itself. VWV also changes by amounts easy to measure in small groups over short time periods:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAtorvastatin significantly reduced VWV in 3 months\u003c\/strong\u003e in a study with about 20 patients per group (Krasinski et al., 2009).\u003c\/li\u003e\n  \u003cli\u003eEven \u003cstrong\u003eweight loss and blood pressure reduction through diet alone\u003c\/strong\u003e showed significant VWV changes in just 2 years, with a mean reduction in VWV of \u003cstrong\u003e−58.1 mm³\u003c\/strong\u003e (95% confidence interval, −81.0 to −35.1 mm³; \u003cstrong\u003eP\u0026lt;0.001\u003c\/strong\u003e).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eHow Long Should You Stay on Statins?\u003c\/h3\u003e\n\u003cp\u003eOne of the most practical clinical takeaways from this editorial comes from a systematic review (Noyes and Thompson, 2014) of intravascular ultrasound and other methods. It found that atherosclerotic plaque regression with statin therapy — in studies that documented regression — occurred after an \u003cstrong\u003eaverage time of 19.7 months\u003c\/strong\u003e. This suggests that patients should undergo about \u003cstrong\u003e2 years of aggressive lipid (cholesterol) reduction\u003c\/strong\u003e before considering any reduction in statin therapy.\u003c\/p\u003e\n\n\u003ch3\u003eWhy Carotid Plaque Is Easier to Shrink Than Coronary Plaque\u003c\/h3\u003e\n\u003cp\u003eCarotid plaque is \u003cstrong\u003efocal\u003c\/strong\u003e — it grows in patches. This means it can change in \u003cem\u003ethree dimensions\u003c\/em\u003e: thickness, length, and circumferential extent. In fact, carotid plaques change in length (along the axis of blood flow) \u003cstrong\u003e2.4 times faster than they thicken\u003c\/strong\u003e. This three-dimensional flexibility makes them much more sensitive to treatment effects.\u003c\/p\u003e\n\u003cp\u003eCoronary plaques (in the heart's arteries), by contrast, extend around the entire circumference of the artery and along the entire length of the ultrasound pullback — so they aren't focal. Their change over time reduces to a single dimension: \u003cstrong\u003eaverage thickness\u003c\/strong\u003e. This is why carotid plaque is a more practical and sensitive target for measuring treatment response.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eFor patients, these findings have several important implications:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot all carotid ultrasound tests are equal.\u003c\/strong\u003e If your doctor orders a carotid ultrasound, ask what's being measured. A test that reports only IMT may be giving a very incomplete picture of your risk. A test that measures plaque burden (total plaque area or volume) is far more informative.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIMT is not a reliable marker of your risk factor control.\u003c\/strong\u003e Since traditional risk factors explain only a small fraction of IMT, and since IMT progression\/regression doesn't reliably predict events, watching your IMT number go up or down may not tell you whether your treatment is working.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlaque burden is a much better gauge of whether you're being protected.\u003c\/strong\u003e Changes in plaque area and volume respond quickly and measurably to effective treatment — and progression of plaque volume predicts future cardiovascular events.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGive statins time to work.\u003c\/strong\u003e Based on the landmark average of 19.7 months to regression, patients should expect to stay on aggressive lipid-lowering therapy for about \u003cstrong\u003e2 years\u003c\/strong\u003e before considering whether the dose can be safely reduced. Don't stop early.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Editorial Couldn't Prove\u003c\/h2\u003e\n\u003cp\u003eIt's important to understand the limits of this article:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIt's an editorial, not a clinical trial.\u003c\/strong\u003e It presents Dr. Spence's expert interpretation of existing research, not new patient data. Editorials are valuable for synthesis but are a form of expert opinion.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe ELSA-Brasil study still leaves much unexplained.\u003c\/strong\u003e Even with added factors like neck circumference, pulse pressure, and race, the total explained variance (R²) was only 0.3 — meaning 70% of IMT variation remains unexplained. The editorial argues this proves IMT is biologically distinct, but it also highlights how little we understand about what drives IMT.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConflicting definitions across studies.\u003c\/strong\u003e Much of the confusion in this field stems from some studies measuring \"IMT\" in ways that include plaque and others not. This inconsistency has historically muddied the research literature.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMany cited studies predate modern imaging.\u003c\/strong\u003e Some of the studies referenced were conducted with older ultrasound technology and methods.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePotential conflicts of interest.\u003c\/strong\u003e Dr. Spence disclosed receiving grants from the Canadian Institutes of Health Research, the Heart \u0026amp; Stroke Foundation of Canada (Ontario), the National Institutes of Health, and industry grants (Pfizer and Merck). He also received lecture honoraria, travel support, and consulting fees from Bayer, Merck, and Boehringer-Ingelheim, and conducted contract research with multiple pharmaceutical companies. He is also a shareholder and officer of Vascularis Inc.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePopulation diversity limits.\u003c\/strong\u003e While ELSA-Brasil adds valuable data from a Brazilian population, many of the other key studies (Tromsø, ARIC, NOMAS) were conducted in North American or European populations, which may not fully generalize worldwide.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations: What Patients Should Know\u003c\/h2\u003e\n\u003cp\u003eBased on this research, here are practical steps for patients and their families:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk your doctor what your ultrasound actually measures.\u003c\/strong\u003e If you're getting a carotid ultrasound, ask whether it will measure plaque burden (plaque area or volume) and not just IMT. Plaque burden is the measurement that best predicts your risk of heart attack and stroke.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your plaque status.\u003c\/strong\u003e If you have plaque, treatment should be aggressive and monitored. Plaque progression is a warning sign; plaque regression is a good sign.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't be discouraged by a \"stable\" IMT — and don't be falsely reassured.\u003c\/strong\u003e IMT has been shown in meta-analyses to be a weak predictor, and changes in IMT don't reliably predict changes in your risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStick with statin therapy for at least 2 years.\u003c\/strong\u003e The evidence shows plaque regression typically takes an average of about 19.7 months of aggressive lipid lowering. If you're considering stopping or reducing your statin, discuss the \u003cem\u003e2-year timeline\u003c\/em\u003e with your doctor first.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLifestyle changes work — and you can see them.\u003c\/strong\u003e The study showing weight loss and blood pressure reduction through diet reduced vessel wall volume by −58.1 mm³ in 2 years is proof that lifestyle changes produce measurable improvements in your arteries.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eManage the factors that drive plaque.\u003c\/strong\u003e Unlike IMT (which is largely explained by age and sex), plaque burden is strongly driven by treatable factors: smoking, high blood pressure, and high cholesterol. These explained 52-57% of total plaque area in previous studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is the difference between IMT and plaque burden on a carotid ultrasound?\u003c\/h3\u003e\n\u003cp\u003eIMT measures the thickness of the artery wall's inner layers, but standard IMT protocols avoid plaque. Plaque burden measures the actual waxy buildup in the artery. They are biologically distinct: plaque reflects oxidative stress and lifetime risk factors, while IMT largely reflects aging and demographics. Measuring plaque predicts heart attack and stroke risk far better than wall thickness alone.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my doctor before having a carotid ultrasound?\u003c\/h3\u003e\n\u003cp\u003eAsk whether the ultrasound will measure plaque burden — total plaque area or volume — rather than only IMT. A test reporting only IMT may give an incomplete picture of your risk. Also ask how the results will guide your treatment, since plaque progression or regression is a more reliable indicator of whether therapy is working.\u003c\/p\u003e\n\u003ch3\u003eWhy is my IMT not changing even though I am on treatment?\u003c\/h3\u003e\n\u003cp\u003eIMT changes are tiny and slow, about 0.15 mm per year, and ultrasound resolution is only 0.3 mm. Large meta-analyses show IMT progression or regression does not reliably predict heart events. Plaque area or volume changes are much larger and respond quickly to effective treatment, so they are better for monitoring your response.\u003c\/p\u003e\n\u003ch3\u003eHow long should I stay on statins to see plaque regression?\u003c\/h3\u003e\n\u003cp\u003eA systematic review found that atherosclerotic plaque regression with statin therapy, when it occurred, happened after an average of 19.7 months. Therefore, the editorial recommends about 2 years of aggressive cholesterol-lowering before considering reducing or stopping your statin. Always discuss this timeline with your doctor first.\u003c\/p\u003e\n\u003ch3\u003eCan lifestyle changes really make a measurable difference in my arteries?\u003c\/h3\u003e\n\u003cp\u003eYes. A study showed that weight loss and blood pressure reduction through diet alone significantly reduced vessel wall volume by -58.1 mm³ in 2 years. This demonstrates that lifestyle changes produce measurable improvements in artery health. Plaque burden is also strongly driven by treatable factors like smoking, high blood pressure, and high cholesterol.\u003c\/p\u003e\n\u003ch3\u003eDoes a normal IMT mean I have no risk of heart attack or stroke?\u003c\/h3\u003e\n\u003cp\u003eNo. IMT alone is a weak predictor of cardiovascular risk. Even if your IMT is stable or normal, you could still have dangerous plaque. In studies, traditional risk factors explained only a small fraction of IMT, and IMT changes did not predict events. Measuring plaque burden is much more informative for assessing your true risk.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Spence Carotid Ultrasound Phenotypes Are Biologically Distinct\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor:\u003c\/strong\u003e J. David Spence, MD, Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Canada.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e \u003cem\u003eArteriosclerosis, Thrombosis, and Vascular Biology\u003c\/em\u003e, 2015;35:1910-1913. DOI: 10.1161\/ATVBAHA.115.306209\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAccompanied article:\u003c\/strong\u003e Santos IS, Alencar AP, Rundek T, et al. \"Low impact of traditional risk factors on carotid intima-media thickness: the ELSA-Brasil cohort.\" \u003cem\u003eArterioscler Thromb Vasc Biol\u003c\/em\u003e. 2015;35:2054-2059.\u003c\/p\u003e\n\u003cp\u003e© 2015 American Heart Association, Inc.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and is not a substitute for professional medical advice. Always consult your physician about your individual health situation.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47458590982300,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.fi\/products\/carotid-ultrasound-why-measuring-plaque-not-just-artery-wall-thickness-matters-for-your-heart-and-brain-health","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}